Literature DB >> 26583527

Severe Ocular Cowpox in a Human, Finland.

Paula M Kinnunen, Juha M Holopainen, Heidi Hemmilä, Heli Piiparinen, Tarja Sironen, Tero Kivelä, Jenni Virtanen, Jukka Niemimaa, Simo Nikkari, Asko Järvinen, Olli Vapalahti.   

Abstract

Entities:  

Keywords:  Finland; PCR; conjunctivitis; cowpox; cowpox virus; keratitis; orthopoxvirus; rodent; tecovirimat; viruses; vole; zoonoses

Mesh:

Year:  2015        PMID: 26583527      PMCID: PMC4672437          DOI: 10.3201/eid2112.150621

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: We describe cowpox with corneal involvement in a 31-year-old atopic woman who lived in southern Finland and was unvaccinated for smallpox. In August 2009, she noticed irritation and edema in her right eye and sought care from a local physician; she started topical antimicrobial drug therapy and oral cephalexin 2 days later. Over the following week, fever developed (37.6°C –39.0°C), edema developed on half her face, the eye became increasingly painful, and visual acuity decreased. The conjunctiva was severely chemotic and hyperemic, but the cornea was clear and the other eye unaffected. Microbiologic samples taken from the eye 11 days after onset showed neither bacteria nor respiratory viruses. Orbital tomography results were normal. The patient was hospitalized, and broad-spectrum intravenous antimicrobial treatment (meropenem, vancomycin, valacyclovir, and fluconazole) was started, combined with topical corticosteroids and antimicrobial drugs. Within 2 weeks, the conjunctiva showed necrosis, and epithelial erosions appeared in the lower cornea, but visual acuity normalized (Technical Appendix Figure, panels A, B). A strong cytopathic effect was observed in Vero cells infected with conjunctival swab (Technical Appendix Table 1), but the virus was unidentifiable by routine methods. In electron microscopy, cell culture and tear fluid samples contained particles with typical orthopoxvirus (OPV) morphology. PCRs for hemagglutinin () and 14-kDa genes () verified OPV infection. Additional PCRs and sequencing confirmed zoonotic cowpox virus (CPXV) with strain designation FIN/K2009. Nucleotide sequences of the hemagglutinin, thymidine kinase, and A-type inclusion body protein genes were identical to those of CPXV strains T2000 and E1989 previously identified in Finland (). In phylogenetic analysis (Figure), CPXV/FIN/K2009 clustered with strains from Austria and shared ancestry with vaccinia virus. OPV IgG and IgM were detected by immunofluorescence assay () in serum samples up to 5 months after symptom onset (Technical Appendix Table 1).
Figure

Phylogenetic tree of orthopoxviruses constructed on the basis of the hemagglutinin gene; boldface indicates the CPXV strain infecting the patient described in this article. The phylogeny shows that the sequence derived from this patient represents a locally circulating strain that shares ancestry with a few other CPXV strains and vaccinia virus. A maximum-likelihood tree was built with 1,000 bootstraps in MEGA 6.06 software (http://www.megasoftware.net/). MEGA was used to estimate the best nucleotide substitution model (general time reversible plus invariable sites). The sequence dataset was compiled from the Virus Pathogen Resource database (http://www.viprbrc.org) and aligned by using MUSCLE (http://www.ebi.ac.uk/Tools/msa/muscle/). Scale bar indicates nucleotide submissions per site. CPXV, cowpox virus.

Phylogenetic tree of orthopoxviruses constructed on the basis of the hemagglutinin gene; boldface indicates the CPXV strain infecting the patient described in this article. The phylogeny shows that the sequence derived from this patient represents a locally circulating strain that shares ancestry with a few other CPXV strains and vaccinia virus. A maximum-likelihood tree was built with 1,000 bootstraps in MEGA 6.06 software (http://www.megasoftware.net/). MEGA was used to estimate the best nucleotide substitution model (general time reversible plus invariable sites). The sequence dataset was compiled from the Virus Pathogen Resource database (http://www.viprbrc.org) and aligned by using MUSCLE (http://www.ebi.ac.uk/Tools/msa/muscle/). Scale bar indicates nucleotide submissions per site. CPXV, cowpox virus. The patient was started on intravenous polyclonal gammaglobulin and topical trifluorothymidine with in vitro anti-OPV effects; nevertheless, corneal erosions enlarged, corneal stromal edema ensued, and intraocular pressure increased (online Technical Appendix Figure, panel C), suggesting trabeculitis. Topical autologous serum drops had no effect. Periorbital edema slowly resolved, but corneal erosions persisted. Amniotic membrane transplantation (AMT) () was performed 2.5 months after onset. The inferior cornea melted, and the cornea lost transparency (online Technical Appendix Figure, panel D). AMT was repeated twice at 1-month intervals because of corneal thinning. At 3.5 months after symptom onset, tecovirimat (400 mg 2×/d) was given orally for 14 days. Despite treatment, ocular OPV PCR test results remained positive until 9 months after onset (Technical Appendix Table 1), and corneal melting progressed (Technical Appendix Figure, panel E). Corneal collagen cross-linking and a fourth AMT were performed at 5 months after onset with partial success (Technical Appendix Figure, panel F). At 1 year after symptom onset, corneal limbal stem cell deficiency with deep corneal neovascularization was evident. Autologous limbal stem cell transplantation from the patient’s other eye and another AMT were performed, resulting in stable corneal surface 2 months later (Technical Appendix Figure, panel G). Neovascularization regressed, the cornea cleared, and vision improved (Technical Appendix Figure, panels H, I). Cowpox is transmitted to humans sporadically from rodents or cats (). We snap-trapped 23 wild rodents from the yard of the patient’s home and from an adjacent meadow and trapped 136 rodents from 3 other regions 30–100 km from the patient’s home (Technical Appendix Table 2). We also collected 8 environmental samples from the patient’s storehouse. In accordance with the Finnish Act on Use of Animals for Experimental Purposes (62/2006) and the Finnish Animal Experiment Board’s later decision (May 16, 2007), the animal capture technique used is not an animal experiment and requires no ethics license. Diluted blood for IFA was collected from all rodents (), and DNA was extracted from rodent liver and lungs and from environmental samples. One vole and 1 mouse from the meadow were seropositive for OPV; however, no CPXV DNA was amplifiable in the samples from the liver, lungs, or environment (online Technical Appendix Table 2). CPXV infection may manifest in severe ocular forms along with self-limiting cutaneous pocks (). Our patient had keratitis with no other identifiable cause but CPXV. Culture and PCR from early conjunctival samples and serology confirmed the etiologic diagnosis. Our case and that of another report () highlight the challenges of treating cowpox keratitis. Topical and systemic antiviral drugs and AMT appear ineffective during the acute phase. Corneal melting and scarring continued as long as CPXV was observed and until combined limbal stem cell and AMT treatment had favorable outcomes. Anamnesis of therapy-resistant keratitis should include information on rodent contacts. We dated the infection to mid-August (incubation 7–21 days). Catching OPV-IgG–positive rodents close to the patient’s home 2 months after onset showed that OPVs were circulating in the local rodent population and indicated the putative role of CPXV-infected voles as the source of infection. The latest cowpox outbreak in Central Europe involved several humans and pets (). This patient was born in 1977, after Finland ceased smallpox vaccinations. Declining cross-reactive smallpox-vaccination immunity enables emergence of unusual cowpox infections in humans (). Technical Appendix. Diagnostic findings of patient, laboratory findings of sampling from rodents and environment, and images of progressive disease in eye of patient with ocular cowpox, Finland.
  9 in total

1.  Clinicopathological findings in persistent corneal cowpox infection.

Authors:  Sybille Graef; Andreas Kurth; Claudia Auw-Haedrich; Niklas Plange; Winfried V Kern; Andreas Nitsche; Thomas Reinhard
Journal:  JAMA Ophthalmol       Date:  2013-08       Impact factor: 7.389

2.  Treatment of Pseudomonas aeruginosa keratitis with combined corneal cross-linking and human amniotic membrane transplantation.

Authors:  Jaakko S Mattila; Anna Korsbäck; Kari Krootila; Juha M Holopainen
Journal:  Acta Ophthalmol       Date:  2013-08       Impact factor: 3.761

3.  Orthopox virus infections in Eurasian wild rodents.

Authors:  Paula M Kinnunen; Heikki Henttonen; Bernd Hoffmann; Eva R Kallio; Christian Korthase; Juha Laakkonen; Jukka Niemimaa; Airi Palva; Mathias Schlegel; Hanan Sheikh Ali; Paula Suominen; Rainer G Ulrich; Antti Vaheri; Olli Vapalahti
Journal:  Vector Borne Zoonotic Dis       Date:  2011-03-31       Impact factor: 2.133

4.  Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.

Authors:  Anne W Rimoin; Prime M Mulembakani; Sara C Johnston; James O Lloyd Smith; Neville K Kisalu; Timothee L Kinkela; Seth Blumberg; Henri A Thomassen; Brian L Pike; Joseph N Fair; Nathan D Wolfe; Robert L Shongo; Barney S Graham; Pierre Formenty; Emile Okitolonda; Lisa E Hensley; Hermann Meyer; Linda L Wright; Jean-Jacques Muyembe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

5.  Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus.

Authors:  Victoria A Olson; Thomas Laue; Miriam T Laker; Igor V Babkin; Christian Drosten; Sergei N Shchelkunov; Matthias Niedrig; Inger K Damon; Hermann Meyer
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

6.  Detection of human orthopoxvirus infections and differentiation of smallpox virus with real-time PCR.

Authors:  Niina Putkuri; Heli Piiparinen; Antti Vaheri; Olli Vapalahti
Journal:  J Med Virol       Date:  2009-01       Impact factor: 2.327

Review 7.  Poxviruses and the evolution of host range and virulence.

Authors:  Sherry L Haller; Chen Peng; Grant McFadden; Stefan Rothenburg
Journal:  Infect Genet Evol       Date:  2013-10-24       Impact factor: 3.342

8.  Cowpox virus infection in pet rat owners: not always immediately recognized.

Authors:  Christian Becker; Andreas Kurth; Frank Hessler; Harald Kramp; Michael Gokel; Rudolf Hoffmann; Annette Kuczka; Andreas Nitsche
Journal:  Dtsch Arztebl Int       Date:  2009-05-08       Impact factor: 5.594

9.  Cowpox with severe generalized eruption, Finland.

Authors:  Paula M Pelkonen; Kyllikki Tarvainen; Arja Hynninen; Eva R K Kallio; Keikki Henttonen; Airi Palva; Antti Vaheri; Olli Vapalahti
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

  9 in total
  11 in total

1.  What a Difference a Gene Makes: Identification of Virulence Factors of Cowpox Virus.

Authors:  Aistė Tamošiūnaitė; Saskia Weber; Timo Schippers; Annika Franke; Zhiyong Xu; Maria Jenckel; Florian Pfaff; Donata Hoffmann; Maegan Newell; B Karsten Tischer; Martin Beer; Nikolaus Osterrieder
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

2.  New p35 (H3L) Epitope Involved in Vaccinia Virus Neutralization and Its Deimmunization.

Authors:  Yana Khlusevich; Andrey Matveev; Lyudmila Emelyanova; Elena Goncharova; Natalia Golosova; Ivan Pereverzev; Nina Tikunova
Journal:  Viruses       Date:  2022-06-05       Impact factor: 5.818

3.  Cowpox in a human, Russia, 2015.

Authors:  A Y Popova; R A Maksyutov; O S Taranov; T V Tregubchak; A V Zaikovskaya; A A Sergeev; I V Vlashchenko; S A Bodnev; V A Ternovoi; N S Alexandrova; A L Tarasov; N V Konovalova; A A Koroleva; L E Bulychev; O V Pyankov; Y V Demina; A P Agafonov; S N Shchelkunov; V N Miheev
Journal:  Epidemiol Infect       Date:  2016-12-05       Impact factor: 4.434

4.  Experimental Cowpox Virus (CPXV) Infections of Bank Voles: Exceptional Clinical Resistance and Variable Reservoir Competence.

Authors:  Annika Franke; Rainer G Ulrich; Saskia Weber; Nikolaus Osterrieder; Markus Keller; Donata Hoffmann; Martin Beer
Journal:  Viruses       Date:  2017-12-19       Impact factor: 5.048

Review 5.  Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.

Authors:  Jonas D Albarnaz; Alice A Torres; Geoffrey L Smith
Journal:  Viruses       Date:  2018-02-28       Impact factor: 5.048

6.  Classification of Cowpox Viruses into Several Distinct Clades and Identification of a Novel Lineage.

Authors:  Annika Franke; Florian Pfaff; Maria Jenckel; Bernd Hoffmann; Dirk Höper; Markus Antwerpen; Hermann Meyer; Martin Beer; Donata Hoffmann
Journal:  Viruses       Date:  2017-06-10       Impact factor: 5.048

7.  Species-Specific Conservation of Linear Antigenic Sites on Vaccinia Virus A27 Protein Homologs of Orthopoxviruses.

Authors:  Henrike P Ahsendorf; Li L Gan; Kamal H Eltom; Ahmed Abd El Wahed; Sven-Kevin Hotop; Rachel L Roper; Ulrike Beutling; Mark Broenstrup; Christiane Stahl-Hennig; Ludwig E Hoelzle; Claus-Peter Czerny
Journal:  Viruses       Date:  2019-05-29       Impact factor: 5.048

Review 8.  Monkeypox: A Contemporary Review for Healthcare Professionals.

Authors:  Boghuma K Titanji; Bryan Tegomoh; Saman Nematollahi; Michael Konomos; Prathit A Kulkarni
Journal:  Open Forum Infect Dis       Date:  2022-06-23       Impact factor: 4.423

9.  In Vivo Characterization of a Bank Vole-Derived Cowpox Virus Isolate in Natural Hosts and the Rat Model.

Authors:  Saskia Weber; Kathrin Jeske; Rainer G Ulrich; Christian Imholt; Jens Jacob; Martin Beer; Donata Hoffmann
Journal:  Viruses       Date:  2020-02-20       Impact factor: 5.048

10.  Fatal Cowpox Virus Infection in Human Fetus, France, 2017.

Authors:  Audrey Ferrier; Gaelle Frenois-Veyrat; Evelyne Schvoerer; Sandrine Henard; Fanny Jarjaval; Isabelle Drouet; Hawa Timera; Laetitia Boutin; Estelle Mosca; Christophe Peyrefitte; Olivier Ferraris
Journal:  Emerg Infect Dis       Date:  2021-08-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.